In a phase three clinical trial, a drug called sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment, a significant increase in progression-free survival compared with placebo. (Progression-free survival is the length of time a patient lives without worsening of the disease).
from Medical Xpress - latest medical and health news stories https://ift.tt/2EH1kEE
via IFTTT
No comments:
Post a Comment